Medical/Pharmaceuticals
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology
SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
$5M Boost to Innovation in Australia with New Illumina Genomics Lab
New laboratory opens in Melbourne Biomedical Precinct to accelerate the adoption of genomics in healthcare and agriculture inAustralia. MELBOURNE, Australia, Nov. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), the global leader in genomics, today announced the opening of a new, fully eq...
Ascensia Diabetes Care Announce Winner of This is Diabetes Art and Photo Competition
BASEL, Switzerland, Nov. 14, 2021 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, makers of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributors of the Eversense® continuous glucose monitoring (CGM) system, has announced the winner of its This is Diabe...
China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced the financial results for the qu...
Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program, an oral, first-in-class inhibitor ofHematopoietic Progenitor Kinase...
Global Accelerated Ventures, ACTUAL, and Bioassets Partner to Work With Enterprises to Make Total Decarbonization Possible
HIGH QUALITY, CERTIFIED CREDITS COMPLEMENT MEANINGFUL EMISSIONS REDUCTIONS FOR ENTERPRISES TO MEET THEIR NET-ZERO MANDATES GLASGOW, Scotland, Nov. 12, 2021 /PRNewswire/ -- Global Accelerated Ventures (GAV) and ACTUAL are partnering with Bioassets, to integrate high quality, provenanced carbon cr...
Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China
SUZHOU, China, Nov. 12, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical ...
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Nov. 12, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Goldman Sachs and Morgan Stanley to share company's latest development. Details are as follows: ...
The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)
MINSK, Belarus, Nov. 12, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New
Era Biotechnology Co., Ltd. participated in the fourth edition of the China
International Import Expo (CIIE) which opened inShanghai on November 5, 2021.
Hetero and Shenzhen Beimei Pharmaceuticals launch antiviral drug Oselavir® in China
Oseltamivir phosphate is used in the treatment of acute uncomplicated influenza infection in adults, adolescents and children BEIJING, Nov. 12, 2021 /PRNewswire/ -- Hetero, a globally renowned vertically integrated pharmaceutical organization and Shenzhen Beimei Pharmaceuticals jointly announced...
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03
* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...
Planet Innovation acquires BIT Group's North American operations, doubling its medtech manufacturing capacity
MELBOURNE, Australia, Nov. 11, 2021 /PRNewswire/ -- Planet Innovation (PI) has acquired the North American operations of global regulated medical device manufacturer, BIT Analytical Instruments GmbH. The acquisition solidifies PI's commitment to grow its US manufacturing capabilities to suppor...
Tabernacle Health Group Launches Revolutionary Immunity Booster. Natural Health Supplement Avrocil (TM) Treats Cold and Flu Symptoms caused by Upper Respiratory Tract Infections
SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- The pandemic sped up participation in virtual exercise classes acrossthe United States, as countless fitness enthusiasts switched to indoor workouts to avoid viruses, such as those that lead to accelerated upper respiratory tract infections, whose sympto...
Patients benefited from telemedicine during COVID-19, says new white paper from Healint
* Longitudinal surveys conducted via HeRO™, Healint's proprietary real-world patient insights platform, reveal that 84% would choose telemedicine if it was available, with a preference for follow-up consultations * A 9-month follow-up questionnaire was sent to evaluate changes in patients' ex...
Lunit Presents Studies at SITC 2021, Highlighting the Effectiveness of AI in Predicting Response to Immunotherapy in a Clinical Trial Setting
- Lunit to present three abstracts about its AI biomarker platform Lunit SCOPE IO, also to be demonstrated during the event in booth #423 - One immunotherapy combination study adds significant evidence for the potential value of using Lunit SCOPE IO in clinical practice to predict patient res...
Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics
SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry andin-vitro ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small mo...
PNOC Study in Childhood Brain Cancer Enrols First Patient
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at theUniversity of Calif...
Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose, placeab...
Dr. Ivan Puah developed MDC-Sculpt(R) Lipo technique to achieve optimal liposuction results in patients
SINGAPORE, Nov. 11, 2021 /PRNewswire/ -- Dr Ivan Puah, Medical Director at Amaris B. Clinic, who has been performing liposuction, correction surgery and gynecomastia surgery for more than 15 years, has developed a liposuction technique called MDC-Sculpt®️ Lipo technique. This proprietary appro...
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD) jointly announces today that Everest Medicines sponsored (HKEX 1952.HK) Phase2b EVER-132-001 study of sacituzumab govitecan (marketed as Trodelvy® in the United States) met its primary endpoint o...
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 278 media titles]
2026-09-29 09:00HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 278 media titles]
2026-09-28 23:04Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45DOKU Names Himelda Renuat CEO as Ant International's Antom Deepens Strategic Investment in Indonesia's Payments Leader
[Picked up by 274 media titles]
2026-09-24 10:00